S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ATHA Athira Pharma Inc

1.922

0.002 (0.10%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Athira Pharma Charts.

Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Athira Pharma Charts.

Athira Pharma Inc News

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Monday 15 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Thursday 11 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Wednesday 3 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Friday 8 March 2024 (2 months ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Friday 23 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Saturday 17 February 2024 (2 months ago) • Edgar (US Regulatory)

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Friday 9 February 2024 (3 months ago) • GlobeNewswire Inc.

More Athira Pharma Inc News Articles

Woodside Petroleum

Verizon Communications

Australia And New Zealan...

Invesco QQQ Trust Series 1

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions